Status:

COMPLETED

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Pulmonary Disease, Chronic Obstructive

Eligibility:

All Genders

40+ years

Phase:

PHASE3

Brief Summary

The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacer...

Eligibility Criteria

Inclusion

    Exclusion

      Key Trial Info

      Start Date :

      September 1 2001

      Trial Type :

      INTERVENTIONAL

      Allocation :

      ACTUAL

      End Date :

      Estimated Enrollment :

      1829 Patients enrolled

      Trial Details

      Trial ID

      NCT00274547

      Start Date

      September 1 2001

      Last Update

      November 1 2013

      Active Locations (26)

      Enter a location and click search to find clinical trials sorted by distance.

      Page 1 of 7 (26 locations)

      1

      Boehringer Ingelheim Investigational Site

      Birmingham, Alabama, United States

      2

      Carl T. Hayden VA Medical Center

      Phoenix, Arizona, United States

      3

      Southern Arizona VA Health Care System

      Tuscon, Arizona, United States

      4

      VA Long Beach Healthcare System

      Long Beach, California, United States

      Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD) | DecenTrialz